ArticleOncology letters2026
Safety and feasibility of total neoadjuvant FLOT chemotherapy in locally-advanced gastric and gastroesophageal junction cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the leading causes of cancer-related mortality worldwide. While perioperative chemotherapy with the fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen improves survival in resectable gastric and gastroesophageal junction (GEJ) cancer, postoperative treatment is frequently poorly tolerated. Total neoadjuvant chemotherapy (TNT), in which all chemotherapy is delivered prior to surgery, has emerged as a promising alternative. The present study aimed to investigate the safety and feasibility of TNT with FLOT in patients with resectable gastric and GEJ cancer. The study retrospectively analyzed patients who received TNT with FLOT followed by curative surgery at the National Cancer Institute in Kyiv (Ukraine), between October 2017 and October 2021. Primary endpoints included safety and feasibility, assessed by chemotherapy-related adverse events, dose reductions, treatment discontinuation and completion rate. Secondary endpoints included pathological response, R0 resection rate, postoperative morbidity and mortality, and surgical outcomes. A total of 76 patients were included in the study. Of these, 71 patients proceeded to curative-intent surgery after the neoadjuvant stage. Among all included patients, 42 (55.26%) patients completed all eight FLOT cycles, 14 (18.42%) patients completed seven cycles, 10 (13.16%) patients completed six cycles and 5 (6.58%) patients completed five cycles. Common toxicities included leukopenia (76.32% grade 1-2; 21.05% grade 3-4) and nausea (76.32% grade 1-2; 10.53% grade 3-4). An R0 resection was achieved in 66 patients (92.96%) and a complete pathological response in 2 patients (2.82%). In conclusion, TNT with FLOT is a safe and feasible option for resectable gastric and GEJ cancer. It is not associated with an increased rate of severe adverse events and mortality. However, the findings of the present study are not conclusive and further prospective studies should assess its long-term efficacy and integration with targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.